This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): azithromycin, azithromycin (w/chloroquine) (AZCQ)
Zithromax (azithromycin) is an azalide, a subclass of macrolide antibiotics. Zithromax exerts its antimicrobial effects by binding to bacterial 50S ribosomal subunit, thus blocking bacterial protein synthesis. It is given once-daily for a number of indications, though some are treated with a one time dose. Its popularity is driven in part by its very limited dosing requirements in many indications, typically 3 days of QD oral administration.
In 2010, approximately 50,000 prescriptions were written for generic Zithromax in the US, placing it among the top 10 pharmaceutical products by US prescription volume.
According to the US Prescribing Information, Zithromax is active against most common strains of Staphylococcus aureus, Staphylococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Chlamydia trachomatis, and various Mycobacterium species.
Deal Structure: Historical drug revenue includes Zithromax and Zmax.
In April 2010, Pfizer and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp).
Additional information available to subscribers only: